Dr. Reddy’s Laboratories (RDY) Stock Rating Upgraded by ValuEngine

Dr. Reddy’s Laboratories (NYSE:RDY) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Monday.

Separately, Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Dr. Reddy’s Laboratories has an average rating of “Hold” and a consensus target price of $30.51.

How to Become a New Pot Stock Millionaire

Shares of Dr. Reddy’s Laboratories stock opened at $32.73 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.13 and a current ratio of 1.50. The company has a market cap of $5,420.94, a PE ratio of 29.49 and a beta of 0.28. Dr. Reddy’s Laboratories has a twelve month low of $29.83 and a twelve month high of $42.97.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 25th. The company reported $0.41 earnings per share for the quarter. The business had revenue of $596.00 million for the quarter. Dr. Reddy’s Laboratories had a return on equity of 8.79% and a net margin of 6.95%. research analysts expect that Dr. Reddy’s Laboratories will post 1.07 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Lenox Wealth Management Inc. raised its position in shares of Dr. Reddy’s Laboratories by 14.3% during the 4th quarter. Lenox Wealth Management Inc. now owns 11,949 shares of the company’s stock worth $449,000 after purchasing an additional 1,493 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Dr. Reddy’s Laboratories during the 4th quarter worth approximately $621,000. Profund Advisors LLC increased its position in Dr. Reddy’s Laboratories by 55.8% in the 4th quarter. Profund Advisors LLC now owns 22,230 shares of the company’s stock valued at $835,000 after acquiring an additional 7,962 shares during the period. Millennium Management LLC increased its position in Dr. Reddy’s Laboratories by 289.9% in the 4th quarter. Millennium Management LLC now owns 23,890 shares of the company’s stock valued at $897,000 after acquiring an additional 17,763 shares during the period. Finally, Wells Fargo & Company MN increased its position in Dr. Reddy’s Laboratories by 26.2% in the 4th quarter. Wells Fargo & Company MN now owns 25,316 shares of the company’s stock valued at $951,000 after acquiring an additional 5,260 shares during the period. Institutional investors and hedge funds own 13.14% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/04/dr-reddys-laboratories-rdy-stock-rating-upgraded-by-valuengine.html.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply